<DOC>
	<DOCNO>NCT00057356</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , dose range pilot study examine effect conivaptan patient acute decompensated heart failure .</brief_summary>
	<brief_title>Safety Efficacy Study YM087 ( Conivaptan ) Patients With Acute Decompensated Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Patients may male female age 18 year old . Women must postmenopausal surgically sterile . Patients must chronic heart failure least 2 month duration hospitalize treatment worsen heart failure . The primary manifestation worsen heart failure must worsen dyspnea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Chronic Heart Failure</keyword>
	<keyword>YM078</keyword>
</DOC>